Daewoong Pharma Net Assets

Latest as of September 2025: ₩1.00 Trillion KRW ≈ $680.48 Million USD

Daewoong Pharma net assets. Based on the latest financial reports, Daewoong Pharma (069620) has net assets worth ₩1.00 Trillion KRW (≈ $680.48 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩2.26 Trillion ≈ $1.53 Billion USD) and total liabilities (₩1.26 Trillion ≈ $851.43 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Daewoong Pharma to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩1.00 Trillion
% of Total Assets	44.42%
Annual Growth Rate	7.53%
5-Year Change	33.33%
10-Year Change	59.76%
Growth Volatility	8.95

Net Assets of Daewoong Pharma (2007–2024)

Net assets of Daewoong Pharma from 2007 to 2024. This chart illustrates how Daewoong Pharma's net assets have evolved over time, based on quarterly financial data. See 069620 net asset quality index to measure how much of total assets are equity-financed.

Annual Net Assets for Daewoong Pharma (2007–2024)

The table below shows the annual net assets of Daewoong Pharma from 2007 to 2024. For live market cap and overall valuation, see Daewoong Pharma market capitalisation.

Year	Net Assets	Change
2024-12-31	₩926.98 Billion ≈ $628.20 Million	+15.44%
2023-12-31	₩802.97 Billion ≈ $544.16 Million	+8.33%
2022-12-31	₩741.22 Billion ≈ $502.32 Million	+5.53%
2021-12-31	₩702.41 Billion ≈ $476.01 Million	+1.03%
2020-12-31	₩695.25 Billion ≈ $471.16 Million	+9.33%
2019-12-31	₩635.92 Billion ≈ $430.95 Million	+4.62%
2018-12-31	₩607.81 Billion ≈ $411.90 Million	-3.76%
2017-12-31	₩631.54 Billion ≈ $427.98 Million	+4.46%
2016-12-31	₩604.55 Billion ≈ $409.70 Million	+4.19%
2015-12-31	₩580.24 Billion ≈ $393.22 Million	+27.38%
2014-12-31	₩455.51 Billion ≈ $308.69 Million	+4.01%
2013-12-31	₩437.96 Billion ≈ $296.80 Million	+13.29%
2012-12-31	₩386.59 Billion ≈ $261.98 Million	+6.67%
2011-12-31	₩362.42 Billion ≈ $245.60 Million	+29.97%
2008-12-31	₩278.85 Billion ≈ $188.97 Million	+3.44%
2007-12-31	₩269.57 Billion ≈ $182.68 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Daewoong Pharma's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 63567448694000.0% over the analyzed period, indicating profitable operations and earnings retention.

Daewoong Pharma Net Assets Breakdown (December 2024)

Daewoong Pharma net assets breakdown by equity component as of December 2024.

Component	Amount	Percentage
Retained Earnings	₩635.67 Billion	80.00%
Other Components	₩158.97 Billion	20.00%
Total Equity	₩794.64 Billion	100.00%

Daewoong Pharma Competitors by Market Cap

The table below lists competitors of Daewoong Pharma ranked by their market capitalization.

Company	Market Cap
Thai Vegetable Oil Public Company Limited BK:TVO	$797.07 Million
Limin Chemical Co Ltd SHE:002734	$797.27 Million
Fujian Yuanli Active Carbon Co Ltd SHE:300174	$797.30 Million
Shanghai Anoky Group SHE:300067	$797.31 Million
Qiming Information Technology Co Ltd SHE:002232	$796.91 Million
Shanghai Huitong Energy Co Ltd SHG:600605	$796.90 Million
Ardmore Shpng NYSE:ASC	$796.88 Million
Qt Group Oyj HE:QTCOM	$796.78 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Daewoong Pharma's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 802,974,720,740 to 794,639,762,000, a change of -8,334,958,740 (-1.0%).
Net income of 24,734,510,690 contributed positively to equity growth.
Dividend payments of 7,740,654,000 reduced retained earnings.
Other factors decreased equity by 25,328,815,430.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	₩24.73 Billion	+3.11%
Dividends Paid	₩7.74 Billion	-0.97%
Other Changes	₩-25.33 Billion	-3.19%
Total Change	₩-	-1.04%

Book Value vs Market Value Analysis

This analysis compares Daewoong Pharma's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.48x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 2.03x to 1.48x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	₩50328.95	₩102200.00	x
2018-12-31	₩47877.03	₩102200.00	x
2019-12-31	₩50316.93	₩102200.00	x
2020-12-31	₩51194.76	₩102200.00	x
2021-12-31	₩51816.40	₩102200.00	x
2022-12-31	₩54928.72	₩102200.00	x
2023-12-31	₩69785.84	₩102200.00	x
2024-12-31	₩69061.46	₩102200.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Daewoong Pharma utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 3.11%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 1.74%
• Asset Turnover: 0.72x
• Equity Multiplier: 2.49x
Recent ROE (3.11%) is below the historical average (8.21%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2007	22.35%	12.17%	1.23x	1.49x	₩32.57 Billion
2008	12.05%	6.01%	1.13x	1.78x	₩5.61 Billion
2011	14.00%	7.06%	1.43x	1.39x	₩14.34 Billion
2012	8.89%	5.09%	1.39x	1.26x	₩-4.24 Billion
2013	13.47%	8.56%	1.18x	1.34x	₩15.03 Billion
2014	7.12%	4.29%	1.06x	1.57x	₩-12.76 Billion
2015	8.94%	5.11%	0.89x	1.97x	₩-5.08 Billion
2016	5.40%	3.05%	0.77x	2.29x	₩-22.98 Billion
2017	6.08%	3.29%	0.79x	2.34x	₩-20.36 Billion
2018	-3.07%	-1.47%	0.85x	2.44x	₩-64.57 Billion
2019	4.24%	1.98%	0.89x	2.40x	₩-29.93 Billion
2020	2.31%	1.21%	0.77x	2.48x	₩-42.35 Billion
2021	4.30%	2.14%	0.81x	2.47x	₩-32.70 Billion
2022	6.95%	3.30%	0.82x	2.57x	₩-18.56 Billion
2023	15.16%	8.85%	0.88x	1.95x	₩41.44 Billion
2024	3.11%	1.74%	0.72x	2.49x	₩-54.73 Billion

Industry Comparison

This section compares Daewoong Pharma's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $482,635,194,011
Average return on equity (ROE) among peers: 4.00%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Daewoong Pharma (069620)	₩1.00 Trillion	22.35%	1.25x	$796.92 Million
Dongwha Pharm.Co.Ltd (000020)	$360.13 Billion	4.96%	0.24x	$98.24 Million
Yuhan Corp. (000100)	$862.60 Billion	14.22%	0.20x	$3.80 Billion
Yuhan Corp Preferred (000105)	$1.94 Trillion	5.30%	0.27x	$45.29 Million
Yuyu Pharma (000220)	$78.29 Billion	7.52%	0.42x	$40.47 Million
Yuyu Pharma Inc (000225)	$140.54 Billion	5.80%	0.47x	$13.42 Million
Yuyu Pharma Inc (000227)	$117.04 Billion	1.10%	0.32x	$32.52 Million
Ildong Holdings Co Ltd (000230)	$172.99 Billion	13.36%	0.64x	$44.50 Million
Samil Pharm (000520)	$56.08 Billion	-15.27%	1.64x	$107.04 Million
Donga Socio Holdings (000640)	$914.25 Billion	3.56%	0.60x	$380.90 Million
Jw Pharmac (001060)	$188.54 Billion	-0.51%	2.36x	$349.95 Million

About Daewoong Pharma

KO:069620 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$796.92 Million

₩1.18 Trillion KRW

Market Cap Rank

#9593 Global

#247 in Korea

Share Price

₩102200.00

Change (1 day)

+1.09%

52-Week Range

₩99100.00 - ₩194000.00

All Time High

₩272265.92